Biomarkers in head and neck carcinoma

Current Opinion in Oncology

Volumn 9, Issue 3, 1997, Pages 247-256

  Oh, Yun ^a   Mao, Li ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; MICROSATELLITE DNA; PROTEIN P53; RETINOID; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

CANCER GENETICS; CELL CLONE; CHROMOSOME ABERRATION; CYTOGENETICS; HEAD AND NECK CARCINOMA; HUMAN; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0030791157     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199709030-00006     Document Type: Review

References (109)

1. Cancer statistics 1996 [table 1] CA-A Cancer Journal for Clinicians 1996, 46:8.
2. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996, 56:2488-2492. Illustrates progressive chromosomal loss through four histopathologic phases of carcinogenesis to form a genetic progression model for HNSCC. Describes the genetic changes shared by tumors and grossly normal adjacent tissue, proposing expansion of clonal genetic changes as a basis for field cancerization.
3. Pekkola-Heino K, Joensuu H, Klemi P, Grenman R: Relation of DNA ploidy and proliferation rate to radiation sensitivity in squamous carcinoma cell lines. Arch Otol Head and Neck Surg 1994, 120:750-754.
4. Wong G, Stidley C, Dressler L, Castillo M, Crooks L, Bartow S: Predictive value of flow cytometric analysis in DNA contents in patients with locally advanced head and neck. J Laryng Otol 1996, 110:243-248.
5. Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, Drumheller T, Tilley BC, Carey TE: Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes, Chromosomes & Cancer 1994, 9:192-206.
6. Sreekantaiah C, Rao PH, Xu L, Sacks PG, Schantz SP, Chaganti RS: Consistent chromosomal losses in head and neck squamous cell carcinoma cell lines. Genes, Chromosomes & Cancer 1994, 11:29-39.
7. Jin Y, Mertens F, Jin C, Akervall J, Wennerberg J, Gorunova L, Mandahl N, Heim S, Mitelman F: Nonrandom chromosome abnormalities in short-term cultured primary squamous cell carcinomas of the head & neck. Cancer Res 1995, 55:3204-3210. An extensive summary of clonal chromosomal abnormalities found in HNSCC cell lines that were examined in short-term cultures to minimize the risk of culture artifact. Also comments on the relative simplicity of laryngeal cancer abnormalities, suggesting less advanced progression of genetic abnormalities in HNSCCs detected earlier.
8. Meredith SD, Levine PA, Burns JA, Gaffey MJ, Boyd JC, Weiss LM, Erickson NL, Williams ME: Chromosome 11q13 amplification in head and neck squamous cell carcinoma: association with poor prognosis. Arch Otolaryngol Head Neck Surg 1995, 121:790-794.
9. Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD: Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene 1996, 12:31-35.
10. Rubin JS, Qiu L, Etkind P: Amplification of the Int-2 gene in head and neck squamous cell carcinoma. J Laryngol Otology 1995, 109:72-76.
11. Akervall JA, Jin Y, Wennerberg JP, Zatterstrom UK, Kjellen E, Mertens F, Willen R, Mandahl N, Heim S, Mitelman F: Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 1995, 76:853-859.
12. Callender T, el-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG: PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994, 74:152-158.
13. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D: Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors [review]. Genes, Chromosomes & Cancer 1994, 10:231-243.
14. Brzoska PM, Levin NA, Fu KK, Kaplan MJ, Singer MI, Gray JW, Christman MF: Frequent novel DNA copy number increase in squamous cell head and neck tumors. Cancer Res 1995, 55:3055-3059.
15. Lavieille JP, Brambilla E, Riva-Lavieille C, Reyt E, Charachon R, Brambilla C: Immunohistochemical detection of p53 protein in preneoplastic lesions and squamous cell carcinoma of the head and neck. Acta Oto-Laryngologica 1995, 115:334-339.
16. Ahomadegbe JC, Barrios M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995, 10:1217-1227.
17. el-Naggar AK, Lai S, Luna MA, Zhou XD, Weber RS, Goepfert H, Batsakis JG: Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 1995, 64:196-201.
18. Munirajan AK, Tutsumi-Ishii Y, Mohanprasak BK, Hirano Y, Munakata N, Shanmugam G, Tsuchida N: p53 Gene mutations in oral carcinomas from India. Int J Cancer 1996, 66:297-300.
19. Melhem MF, Law JC, el-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S, Whiteside TL: Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995, 146:1170-1177.
20. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forastiere AA, Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. New Engl J Med 1995, 332:712-717. The striking association between HNSCC and tobacco-smoking or chronic alcohol ingestion now has at least one molecular explanation. A significant increase in p53 mutations is demonstrated in HNSCC patients who smoke or drink.
21. Nylander K, Schildt EB, Eriksson M, Magnusson A, Mehle C, Roos G: A non-random deletion in the p53 gene in oral squamous cell carcinoma. Br J Cancer 1996, 73:1381-1386.
22. Mao EJ, Schwartz SM, Daling JR, Oda D, Tickman L, Beckmann AM: Human papilloma viruses and p53 mutations in normal pre-malignant and malignant oral epithelia. Int J Cancer 1996, 69:152-158.
23. Nylander K, Milsson P, Mehle C, Roos G: p53 Mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995, 71:826-830.
24. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, Heyne K, Shin HJ, Ro JY, Goepfert H, Hong WK, Hittelman WN: p53 Expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996, 88:519-529. Used very explicit criteria for immunohistochemistry detection of p53 expression. Patients with a very slight increase above background in tumor p53 expression were evaluated as a group. demonstrating significantly worse outcomes. Most other studies of p53 immunohistochemistry in HNSCC have tried to find prognostic correlates of gross p53 overexpression without success.
25. Huang TS, Kuo ML, Shew JY, Chou YW, Yang WK: Distinct p53-mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 1996, 13:625-632.
26. Spandau DF: Distinct conformations of p53 are observed at different stages of keratinocyte differentiation. Oncogene 1994, 9:1861-1868.
27. Sauter ER, Ridge JA, Trock B, Cleveland D, Whitley KV, Mohr RM, Klein-Szanto A: Overexpression of the p53 gene in primary and metastatic head and neck carcinomas. Laryngoscope 1995, 105:653-656.
28. Gallo O, Bianchi S, Giovannucci-Uzzielli ML, Santoro R, Lenzi S, Salimbeni C, Abbruzzese M, Alajmo E: p53 Oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. Br J Cancer 1995, 71:1008-1012.
29. Nylander K, Stenling R, Gustafsson H, Zackrisson B, Roos G: p53 Expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 1995, 75:87-93.
30. Lavieille JP, Lubin R, Soussi T, Reyt E, Brambilla C, et al.: Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res 1996, 16:2385-2388.
31. Granetto C, ottaggio L, Abbondandolo A, Bonatti S: p53 Accumulates in micronuclei after treatment with a DNA breaking chemical, methylnitrosourea, and with the spindle poison, vinblastine. Mutation Res 1996, 352:61-64.
32. Wolf DC, Gross EA, Lyght O, Bermudez E, Recio L, Morgan KT: Immunohistochemical localization of p53, PCNA, and TGF-α proteins in formaldehyde-induced rat nasal squamous cell carcinomas. Toxicol Appl Pharmacol 1995, 132:27-35.
33. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F, Soussi T: Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996, 88:1228-1233. A subset of patients whose HNSCC tumor cells accumulate p53 also demonstrate serum antibodies to p53. The presence of these antibodies appears to be a more powerful prognosticator of relapse and death than various immunohistochemistry studies of p53 accumulation.
34. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocked E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
35. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995, 375:506-510.
36. Zhang SY, Klein-Szanto AJ, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of alternation in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 1994, 54:5050-5053.
37. Lydiatt WM, Murty VV, Davidson BJ, Xu L, Dyomina K, Sacks PG, Schantz SP, Chaganti RS: Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes, Chromosomes & Cancer 1995, 13:94-98.
38. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995, 1:686-692. Offers a mechanism of inactivation for a tumor suppressor gene very commonly dysfunctional in human cancers. Implies that other tumor suppressor genes may be inactivated by methylation and amenable to pharmacologic reactivation.
39. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55:4525-4530.
40. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head & neck squamous cell carcinoma. Cancer Res 1996, 56:3630-3633. Use of a new monoclonal antibody for immunohistochemistry of p16 expression. This method will allow quick and simple corroboration of p16 inactivation on tumor resection or biopsy specimens.
41. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al.: Frequency of homozygous deletion at P16/CDKN2 in primary human tumours. Nature Genetics 1995, 11:210-212. Deletions in the p16 gene are described in 75% of HNSCC cell lines and 19% of primary tumors as well, suggesting deletion as at least a partial explanation for p16 inactivation.
42. Herman JG, Jen J, Merlo A, Baylin SB: Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996, 56:722-727.
43. Loughran O, Malliri A, Owens D, GAllimore PH, Stanley MA, Ozanne B, Frame MC, Parkinson EK: Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene 1996, 13:561-568.
44. Liggett WH Jr, Sewell DA, Rocco J, Ahrendt SA, Koch W, Sidransky D: p16 And p16 β are potent growth suppressors of head & neck squamous cell carcinoma in vitro. Cancer Res 1996, 56:4119-4123. Re-establishing p16 or p16-β activity by transfection into three HNSCC cell lines led to G1 arrest, supporting the hypothesis that p16 is a tumor suppressor gene inactivated in neoplasia. The p16-β induction of growth arrest appears to be independent of retinoblastoma activity.
45. ARF) are also transcriptional variants of the same gene. In the murine system, both from the same gene utilizing alternative reading frames, implying an evolutionary co-conservation and a necessity for dual expression in cell cycle control.
46. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: MAD-related genes in the human. Nature Genetics 1996, 13:347-349.
47. Briskin KB, Fady C, Mickel RA, Wang M, Lichtenstein A: Inhibition of head and neck squamous cell carcinoma cell lines by transforming growth factor-beta. Otolaryngology-Head & Neck Surgery 1995, 112:728-734.
48. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM: Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996, 67:333-338.
49. Duffey DC, Calcaterra TC, Lichtenstein AK: Regulation of transforming growth factor-beta 1-mediated apoptosis in head and neck squamous cell carcinoma. Laryngoscope 1996, 106:889-894.
50. Rollins BJ, O'Connell TM, Bennett G, Burton LE, et al.: Environment-dependent growth inhibition of human epidermal keratinocytes by recombinant human transforming growth factor-beta. J Cell Physiol 1989, 139:455-462.
51. Zhang Y, Feng X, We R, Derynck R: Receptor-associated MAD homologues synergize as effectors of the TGF-β response. Nature 1996, 383:168-172.
52. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86:543-552. Implicates MADR2 mutation in TGF-β-resistant tumor growth. MADR2 is one in a family of the MAD-related genes implicated in TGF-β-signal transduction.
53. Garrigue Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M: Missence mutations of transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995, 55:3982-3987. The first description of simple mutation inactivating TGF-β-type II receptors in HNSCC, offering an explanation for TGF-β resistance in HNSCC.
54. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL: MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996, 87:1215-1224. Evidence that a mutation in a MADR2 phosphorylation site can block normal TGF-β signaling by stabilizing MADR2 binding to the TGF-β-type II receptors and preventing nuclear accumulation of MADR2. A thorough dissection of the signal transduction pathway linking TGF-β-type II receptors to MADR2.
55. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN: Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 1995, 14:5646-5659. Describes how both c-myc and MAD proteins are able to form heterodimers with the MAX protein to promote cell transformation or growth arrest. Suggests that the balance of MAD1, MAD3, and MAD4 with c-myc during muring embryogenesis is important in determining cell differentiation.
56. Hurlin PJ, Foley KP, Ayer DE, Eisenman RN, Hanahan D, Arbeit JM: Regulation of myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 1995, 11:2487-2501.
57. Lymboussaki A, Kaipainen A, Hatva E, Vastrik I, Jeskanen L, Jalkanen M, Werner S, Stenback F, Alitalo R: Expression of Mad, an antagonist of Myc oncoprotein function, in differentiating keratinocytes during tumorigenesis of the skin. Br J Cancer 1996, 73:1347-1355.
58. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rosenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
59. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittelman WN, Hong WK, Lotan R, Mao L: DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996, 56:2519-2521. A systematic analysis of multiple HNSCC cell lines to rule out DPC4 mutations as a cause of the frequent LOH on 18q21.
60. Mao L, Fan Y, Lotan R, Hong WK: Frequent abnormalities of FHIT, a candidate tumor suppressor gene in head and neck cancer cell lines. Cancer Res 1996, 56:5128-5131.
61. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM: FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci U S A 1996, 93:9770-9775. First to implicate alterations of the tumor suppressor gene FHIT in HNSCC, using RT-polymerase chain reaction and fluorescence in situ hybridization on interphase nuclei with probes for different exons.
62. Clark JW, Glicksman AS, Wanebo HJ: Systemic and adjuvant therapy for patients with pancreatic carcinoma. Cancer 1996, 78(suppl 3):688-693.
63. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective: a continuing challenge. Cancer 1996, 78(suppl 3):580-591.
64. Kiaris H, Spandidos DA, Jones AS, Vaughan ED, Field JK: Mutations, expression of genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 1995, 72:123-128.
65. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer MT: ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994, 104(pt 1):1337-1347.
66. Paterson IC, Eveson JW, Prime SS: Molecular changes in oral cancer may reflect aetiology and ethnic origin. Eur J Cancer 1996, 326:150-153.
67. McDonald JS, Jones H, Pavelic ZP, Pavelic LJ, Stambrook PJ, Gluckman JL: Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994, 23:342-346.
68. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S: Bcl-2 expression correlates with favorable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Research 1996, 16:2403-2408.
69. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD, Franklin WA: Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, & Ki-67 with survival & metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996, 122:627-632.
70. Li X, Lee NK, Ye YW, Waber PG, Schweitzer C, Cheng QC, Nisen PD: Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 1994, 86:1524-1529.
71. Maestro R, Piccinin S, Doglioni C, Gasparotto D, Vukosavljevic T, Sulfaro S, Barzan L, Boiocchi M: Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer Res 1996, 56:1146-1150.
72. Hui AB, Lo KW, Leung SF, Choi PH, Fong Y, Lee JC, Huang DP: Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res 1996, 56:3225-3229.
73. Ishwad CS, Ferrell RE, Rossie KN, Appel BN, Johnson JT, Myers EN, Law JC, Srivastava S, Gollin SM: Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. Int J Cancer 1996, 69:1-4.
74. Roz L, Wu CL, Porter S, Scully C, Speight P, Read A, Sloan P, Thakker N: Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res 1996, 56:1228-1231. Demonstrates in oral dysplastic lesions, three noncontiguous regions of deletions that overlap with those defined for oral squamous cell carcinomas. Adds credence to the supposition of tumor suppressor genes on chromosome 3p being inactivated early during carcinogenesis.
75. Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D: Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 1996, 56:2484-2487. Evidence for common clonal origin in some cases of multiple synchronous and metachronous HNSCC tumors. Implies that molecular genetic screening of local tissue may help in the future help to detect early recurrence or new tumors in some patients.
76. Waber PG, Lee NK, Nisen PD: Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the von-Hippel Lindau tumor suppressor gene in head and neck cancer. Oncogene 1996, 12:365-369.
77. Emilion G, Langdon JD, Speight P, Partridge M: Frequent gene deletions in potentially malignant oral lesions. Br J Cancer 1996, 73:809-813.
78. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittel man W, Hong WK: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions & their value in cancer risk assessment. Nature Medicine 1996, 2:682-685. Loss of heterozygosity at either or both 9p21 or 3p14 was identified in premalignant oral lesions from 51% of patients. Of these patients. 37% developed HNSCC, whereas only 6% of patients without LOH developed HNSCC. In a population with a 50% prior probability of recurrent or metachronous tumor. microsatellite analysis of 9p21 and 3p14 would give a positive predictive value of about 86%. Microsatellite analysis and similar techniques such as this appear to be promising strategies for prognostication and therapy guidance.
79. Rowley H, Jones AS, Field JK: Chromosome 18: a possible site for a tumour suppressor gene deletion in squamous cell carcinoma of the head and neck. Clinical Otolaryngol 1995, 20:266-271.
80. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives [review]. J Natl Cancer Instit 1995, 87:1114-1125.
81. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proceed Natl Acad Sci U S A 1994, 91:9871-9875.
82. Ishwad CS, Ferrell RE, Rossie KM, Appel BN, Johnson JT, Myers EN, Law JC, Srivastava S, Gollin SM: Microsatellite instability in oral cancer. Int J Cancer 1995, 64:332-335.
83. Field JK, Kiaris H, Howard P, Vaughan ED, Spandidos DA, Jones AS: Microsatellite instability in squamous cell carcinoma of the head and neck. Br J Cancer 1995, 71:1065-1069.
84. Mutirangura A, Supiyaphun P, Trirekapan S, Sriuranpong V, Sakuntabhai A, Yenrudi S, Voravud N: Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996, 56:3530-3533. Demonstrates that telomerase activity can be detected in premalignant oral lesions in association with phenotypic progression to malignancy and degree of dysplasia implicating it in promotion carcinogenesis.
85. Mao L, EI-Naggar AK, Fan YH, Hong WK: Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 1996, 56:5600-5604. Telomerase activity was found ubiquitously in dysplastic and hyperplastic lesions and absent in normal tissues; this distinct contrast is more in keeping with the literature regarding telomerase activity. Suggests telomerase reactivation is a very early phenomenon in carcinogenesis.
86. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D: Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res 1996, 565720-5722. The high rate of telomerase activity in even premalignant oral lesions makes it an attractive target for screening; however, the low rate of detection and high false-negative rate in oral rinses limits its usefulness. The false-negative results may be partially related to salivary RNAse activity. Rinses were also positive in 6% of control patients.
87. Oridate N, Esumi N, Lotan D, Hing WK, Rochette, Egly C, Chambon P, Lotan R: Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck. Oncogene 1996, 12:2019-2028.
88. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK: Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995, 332:1405-1410. Restoration of RAR-β expression in premalignant oral lesions following treatment with isoretinoin is also associated with a clinical response. These results raise RAR-β as a candidate biomarker to be used in HNSCC chemoprevention trials.
89. Shindoh M, Chiba I, Yasuda M, Saito T, Funaoka K, Kohgo T, Amemiya A, Sawada Y, Fujinaga K: Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Cancer 1995, 76:1513-1521.
90. Snijders PJ, Scholes AG, Hart Ca, Jones AS, Vaughan ED, Woolgar JA, Meijer CJ, Walboomers JM, Field JK: Prevalence of mucosotropic human papillomaviruses in squamous cell carcinoma of the head and neck. Int J Cancer 1996, 66:464-469.
91. Chiba I, Shindoh M, Yasuda M, Yamazaki Y, Amemiya A, Sato Y, Fujinaga K, Notani K, Fukuda H: Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 1996, 12:1663-1668. Mutation in the p53 gene or HPV-16 DNA is frequent in oral squamous cell carcinoma (40%). and HPV infection as well as mutation appears to be frequent causes for p53 inactivation in development of HNSCCs. Also described is a poorer prognosis for patients with tumors that were both p53 mutation-negative and HPV-negative.
92. Kaur J, Ralhan R: Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer 1995, 63:774-779.
93. Kozacko MF, Mang TS, Schally AV, Priore RL, Liebow C: Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer. Proc Natl Acad Sci U S A 1996, 93:2953-2957.
94. Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, Itoh K, Ishikawa T: Expression of the MAGE gene family in human head-and-neck squamous-cell carcinoma. Int J Cancer 1995, 64:304-308.
95. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exper Med 1995, 182:689-698.
96. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995, 2:167-175.
97. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhange ZA, Tobi H, Braakhuis BJ, Snow GB: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Instit 1996, 88:530-535.
98. Foulkes WD, Brunet JS, Kowalski LP, Narod SA, Franco EL: Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. Int J Cancer 1995, 63:769-773.
99. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995, 332:429-435. Molecular analysis of p53 mutations seems to allow detection of microscopically undetectable tumor cells in surgical margins and lymph nodes from HNSCC patients following resection. Appears to predict patients at a substantially increased risk of local recurrence.
100. Boyle JO, Mao L, Brennan JA, Koch WM, Eisele DW, Saunders JR, Sidransky D: Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 1994, 168:429-432.
101. Wilson GD, Richman PI, Dische S, Saunders MI, Robinson B, Daley FM, Ross DA: p53 Status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br J Cancer 1995, 71:1248-1252.
102. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 1995, 55:2995-2997.
103. Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, Zoumpourlis JR, Woolgar J, Vaughan ED, Spandidsos DA, Jones AS: Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. Br J Cancer 1995, 72:1180-1188. Allelic loss was quantitated as the fractional allele loss (number of chromosome arms on which allele loss is noted). Fractional allele loss above the mean value of 0.22 correlates with local metastasis and decreased survival. This method initiates attempts to measure the risk of progressive HNSCC disease with progressive chromosomal loss.
104. Soder AI, Hopman AH, Ramaekers FC, Conradt C, Bosch FX: Distinct nonrandom patterns of chromosomal aberrations in the progression of squamous cell carcinomas of the head and neck. Cancer Res 1995, 55:5030-5037. Enumerates the chromosomal abnormalities associated with HNSCC metastatic disease to lymph nodes. Overexpression of p53 protein also correlated well with an increased incidence of chromosomal imbalances and also qualified as a secondary risk factor for metastatic disease.
105. Welkoborsky HJ, Hinni M, Dienes HP, Mann WJ: Potential early markers of carcinogenesis in the mucosa of the head and neck using exfoliative cytology. Ann Otol Rhinol Laryngol 1995, 104:503-510.
106. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995, 55:975-978. Cyclin D1 is thought to be important in activating retinoblastoma-repressed cell cycle transcriptional factors. Overexpression of cyclin D1 is associated with cell proliferation and here is also associated with aggressive HNSCC tumors resulting in decreased disease-free interval and survival.
107. Wilson KM, Sonke RL, McDonald JS, Stambrook PJ, Pavelic LJ, Klusman P, Okum E, Neenan J, Gluckman JL, Pavelic ZP: Stage of disease confounds apparent relationship between levels of N-ras and duration of survival in head and neck tumours. Eur J Cancer 1996, 326:73-75.
108. Bongers V, Snow GB, de Vries N, Braakhuis BJ: Potential early markers of carcinogenesis in the mucosa of the head and neck using exfoliative cytology. J Pathol 1996, 178:284-289.
109. Xu XC, Zile MH, Lippman SM, Lee JS, Lee JJ, Hong WK, Lotan R: Antiretinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res 1995, 55:5507-5511.